Clinical Trials Directory

Trials / Completed

CompletedNCT00477308

Genotyping Directed Salvage Therapy in Children Who Have Failed Dual NRTIs

Clinical, Immunologic and Virological Outcomes of Genotyping Directed Salvage Therapy in Children Who Have Failed Dual NRTIs

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
95 (actual)
Sponsor
The HIV Netherlands Australia Thailand Research Collaboration · Academic / Other
Sex
All
Age
1 Year – 18 Years
Healthy volunteers
Not accepted

Summary

In HIV-NAT 013 phase I study, genotyping was performed in 95 children on dual NRTI which showed that almost all children had resistance to NRTi. The HIV-NAT 013 phase II is a follow up study to evaluate treatment outcome after salvage therapy and the evolution of mutations.

Detailed description

The HIV-NAT 013 study (conducted in 2003) evaluated prevalence and pattern of RT mutation in 95 children treated with dual NRTI. The study showed almost all children to have some degree of NRTI resistance and 40% with multi NRTI resistance. The mutation reported was major mutation. After the study, the patients were managed based on the physician's judgment using genotyping results. The 95 patients in HIV-NAT 013 are categorized into 3 groups. 1. No viral resistance 2. Low grade resistance with or without clinical/ immunological failure 3. High grade resistance with or without clinical/ immunological failure. There are limited prospective studies evaluating outcome of decision regarding salvage therapy after genotyping results There are also new mutations that are not considered major mutation that may affect treatment outcome Knowledge learned from this study will benefit Thai children with NRTI resistance by helping pediatricians better choose salvage treatment options

Conditions

Interventions

TypeNameDescription
PROCEDUREsalvage therapy

Timeline

Start date
2006-01-01
Primary completion
2009-04-01
Completion
2009-04-01
First posted
2007-05-23
Last updated
2020-07-17

Locations

3 sites across 1 country: Thailand

Source: ClinicalTrials.gov record NCT00477308. Inclusion in this directory is not an endorsement.